Development and validation for the quantitative determination of xanthine oxidoreductase inhibitor topiroxostat by LC-MS/MS and its clinico-pharmacokinetic study.

Xiangling Feng,Yan Cao,Yufeng Ding,Heng Zheng
DOI: https://doi.org/10.1016/j.jpba.2020.113470
IF: 3.571
2020-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:•A sensitive and efficient method was developed and validated for topiroxostat by HPLC-MS/MS for the first time.•FDA-EMA guided validation demonstrated the repeatability and reliability of the method.•Topiroxostat was determined with run time of 4.0 min and lower limit of quantification of 1 ng/mL.•Simple pretreatment for plasma samples.•Successful employment of the method in human pharmacokinetic studies.
What problem does this paper attempt to address?